Lyvgen Pharma

Focus: Lyvgen Pharma is an immuno-oncology antibody specialist founded in 2022, headquartered in Shanghai and focused on oncology therapeutics. The company is in early clinical stages with a pipeline of monoclonal antibodies and combination therapies targeting solid tumors.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About Lyvgen Pharma

AI assessmentNot Hiring

No open roles listed right now. Follow Lyvgen Pharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

7 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

LVGN6051

Cancer

Phase 1

Clinical Trials (1)

NCT04694781Study of LVGN6051 (CD137 Agonist Antibody) in Advanced or Metastatic Malignancy

Phase 1

Help build intelligence for Lyvgen Pharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a newly founded (2022) immuno-oncology specialist with active clinical programs across multiple cancer indications
Exposure to emerging checkpoint inhibitor and bispecific antibody development in a high-growth therapeutic area
Potential to build functional expertise in a focused, mAb-centric company with 6 active trials spanning Phase 1–2

Watch Out For

Company has zero active job postings and minimal disclosed funding/employee data, signaling either very early hiring stage or limited transparency
No marketed products, revenues, or Phase 3 programs—career progression may be limited if pipeline falters or funding stalls
Shanghai headquarters and recent founding (2022) present operational, visa sponsorship, and stability unknowns for Western talent

Generated by Claude from Lyvgen Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

LVGN7409

Cancer

Phase 1

Clinical Trials (1)

NCT05152212Study of LVGN7409 (CD40 Agonist Antibody) in Locally Advanced, Metastatic or Recurrent/Refractory Malignancy

Phase 1

LVGN7409

Cancer

Phase 1

Clinical Trials (1)

NCT04635995Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy

Phase 1